MacroGenics, Inc.
http://www.macrogenics.com/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From MacroGenics, Inc.
US FDA’s Three Review Speeds: Standard, Priority – And Oncology
FDA’s oncology review team likes to do things its own way – and at its own hyper fast pace.
FDA Approval Opens Up Gastric Cancer To Daiichi Sankyo/AZ’s Enhertu
The two companies can now market their HER-2 targeting antibody-drug conjugate in its second tumor type as they look to expand beyond breast cancer.
The US FDA’s Nifty Fifty
FDA has approved over 50 new molecular entities in a year for the second time – a truly remarkable job amid a global pandemic. But will 2021 be a tougher year?
Keeping Track: Myovant, Almirall, MacroGenics Nab Novel Approvals; Novartis’ Inclisiran Delayed
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Vaccines
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Raven Biotechnologies